Etana Receives First Shipment of MCV4 Menhycia Vaccine from CanSino

Etana has received its first imported shipment of the MCV4 (Menhycia) vaccine on Thursday, October 2, 2025 from its global partner, CanSino. The arrival of this vaccine marks an important step in strengthening protection for the Indonesian people against meningitis.

MCV4 Menhycia is a conjugate vaccine that can be administered to children from 3 months to 1 year of age, providing early protection from a young age. Furthermore, the vaccine has also been certified Halal by the Indonesian Ulema Council (MUI), giving the public greater confidence in its use.

Meningitis is known as a serious infectious disease that can affect anyone, both children and adults. This disease is of particular concern for prospective Hajj and Umrah pilgrims, as long journeys and large gatherings can increase the risk of transmission.

Etana believes that everyone deserves better access to healthcare. Through the availability of the MCV4 Menhycia vaccine, Etana not only supports the government’s disease prevention programs but also provides real solutions to ensure easier access to healthcare for the Indonesian people.